Evidence map›Paper›PMID 40943214›Full record

ArticleInternational journal of molecular sciences2025

Inorganic Silica Nanoparticles Increase Lysosomal Biology and Protease Activity.

Anastasiia O Syrocheva, Valentina I Gorbacheva, Vera S Egorova, Andrey A Zamyatnin, Alessandro Parodi, Ekaterina P Kolesova

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Anastasiia O SyrochevaResearch Center for Translational Medicine, Sirius University of Science and Technology, Sochi 354340, Russia.ORCID 0009-0008-5035-8445
Valentina I GorbachevaResearch Center for Translational Medicine, Sirius University of Science and Technology, Sochi 354340, Russia.
Vera S EgorovaResearch Center for Translational Medicine, Sirius University of Science and Technology, Sochi 354340, Russia.ORCID 0000-0003-1666-8147
Andrey A ZamyatninFaculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, Moscow 119234, Russia.ORCID 0000-0002-3046-4565
Alessandro ParodiResearch Center for Translational Medicine, Sirius University of Science and Technology, Sochi 354340, Russia.ORCID 0000-0003-0985-6545
Ekaterina P KolesovaResearch Center for Translational Medicine, Sirius University of Science and Technology, Sochi 354340, Russia.ORCID 0000-0002-6730-1858

Funding

Russian Science Foundation grant # 24-24-20102
6 · The paper itself

Abstract

The use of nanoparticles has revolutionized drug delivery by enabling targeted and controlled therapeutic release. However, their interactions with intracellular organelles, particularly lysosomes, are not yet fully understood. This study delineates the differential effects of two widely used nanocarriers-mesoporous silica (MSNs) and albumin (ANPs) nanoparticles-on lysosomal biology, with a focus on the expression and activity of cathepsins (CtsB and CtsD), which are key proteases involved in protein degradation and maintaining cellular balance. These two types of nanoparticles, differing in their material and degradability, exhibit distinct behaviors inside the cell. We demonstrate that inorganic MSNs cause significant changes in lysosomal function by altering lysosomal content and cathepsin levels, without triggering lysosomal membrane permeabilization-a typical response to organic particle stress. In contrast, ANPs-which are susceptible to lysosomal cathepsin degradation-induce milder changes in cathepsin expression and maintain lysosomal integrity. Our results highlight that the composition of nanocarriers plays a pivotal role in modulating lysosomal protease activity and maintaining overall cellular homeostasis, highlighting the importance of these parameters in the rational design of drug delivery platforms.

Indexed as

LysosomesNanoparticlesPeptide HydrolasesSilicon DioxideAnimalsCathepsin BCathepsin DCathepsinsDrug CarriersHumansCathepsin BCathepsin DCathepsinsDrug CarriersPeptide HydrolasesSilicon Dioxidealbumin nanoparticlescathepsinsdrug deliverylysosomesmesoporous silica nanoparticlesnanocarriers

Identifiers

PMID40943214
PMCPMC12428692

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.